Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA
Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae spe...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2021-06-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/27/6/20-3206_article |
id |
doaj-4abebdbe81af4eb3abbb1c5d19dc195a |
---|---|
record_format |
Article |
spelling |
doaj-4abebdbe81af4eb3abbb1c5d19dc195a2021-05-20T01:04:35ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592021-06-012761588159710.3201/eid2706.203206Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USAMariana M. LanataHuanyu WangKathy EverhartMelisa Moore-ClingenpeelOctavio RamiloAmy Leber Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae–positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens. https://wwwnc.cdc.gov/eid/article/27/6/20-3206_articleMycoplasma pneumoniaemacrolide sensitivitymacrolide resistancemolecular detectionchildrendisease severity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariana M. Lanata Huanyu Wang Kathy Everhart Melisa Moore-Clingenpeel Octavio Ramilo Amy Leber |
spellingShingle |
Mariana M. Lanata Huanyu Wang Kathy Everhart Melisa Moore-Clingenpeel Octavio Ramilo Amy Leber Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA Emerging Infectious Diseases Mycoplasma pneumoniae macrolide sensitivity macrolide resistance molecular detection children disease severity |
author_facet |
Mariana M. Lanata Huanyu Wang Kathy Everhart Melisa Moore-Clingenpeel Octavio Ramilo Amy Leber |
author_sort |
Mariana M. Lanata |
title |
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA |
title_short |
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA |
title_full |
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA |
title_fullStr |
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA |
title_full_unstemmed |
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA |
title_sort |
macrolide-resistant mycoplasma pneumoniae infections in children, ohio, usa |
publisher |
Centers for Disease Control and Prevention |
series |
Emerging Infectious Diseases |
issn |
1080-6040 1080-6059 |
publishDate |
2021-06-01 |
description |
Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae–positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens.
|
topic |
Mycoplasma pneumoniae macrolide sensitivity macrolide resistance molecular detection children disease severity |
url |
https://wwwnc.cdc.gov/eid/article/27/6/20-3206_article |
work_keys_str_mv |
AT marianamlanata macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa AT huanyuwang macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa AT kathyeverhart macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa AT melisamooreclingenpeel macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa AT octavioramilo macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa AT amyleber macrolideresistantmycoplasmapneumoniaeinfectionsinchildrenohiousa |
_version_ |
1721436106795253760 |